RxDoctor Payments DataLook up a doctor →

Robert Schilz, DO

Critical Care Medicine · Cleveland, OHNPI 1972523538

Payments from drug & device makers

$777,555in general payments, 2019–2025

Across 645 payments — averaging $1205.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$280K
  • Merck$150K
  • Actelion Pharmaceuticals US, Inc.$137K
  • Roche Products Limited$137K
  • Bayer$36K
  • Baxter Healthcare$35K
  • plus $2K from 36 others

What the payments were for

  • Consulting fees$37,70911%
  • Speaking & faculty fees$279,42379%
  • Travel & lodging$25,2677%
  • Food & beverage$13,3124%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$777,555 in reported general payments places this provider in the 95th percentile of 285 critical care medicine providers in Ohio.

See all critical care medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$36,125
Medicare patients
231
Services billed
582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag156$3,426,800
Tyvaso DpiTreprostinil141$3,377,436
OpsumitMacitentan263$3,352,336
Orenitram ErTreprostinil Diolamine162$1,323,477
AdempasRiociguat81$1,114,474
Ambrisentan222$673,103
Tadalafil452$307,906
LetairisAmbrisentan24$306,437
WinrevairSotatercept-Csrk16$223,661
TracleerBosentan12$147,496
OpsynviMacitentan/Tadalafil11$142,137
RemodulinTreprostinil Sodium12$58,801
Sildenafil Citrate90$15,564
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$9,871
Spiriva RespimatTiotropium Bromide11$5,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Tracleer, Opsynvi$137,477$7,068,768442 claims
BayerAdempas$36,210$1,114,47481 claims
GileadLetairis$44$306,43724 claims
MerckWinrevair$149,784$223,66116 claims
United Therapeutics CorporationRemodulin$280,286$58,80112 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$255$15,11823 claims
GSKBreo Ellipta$63$4,16412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 285 critical care medicine providers in Ohio.

Other critical care medicine in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →